Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$23.65 - $35.63 $2.53 Million - $3.82 Million
107,089 New
107,089 $3.78 Million
Q2 2023

Aug 14, 2024

BUY
$8.53 - $14.28 $754,998 - $1.26 Million
88,511 Added 82.65%
195,600 $2.2 Million
Q1 2023

May 15, 2024

BUY
$10.88 - $15.0 $3.96 Million - $5.45 Million
363,600 New
363,600 $4.19 Million
Q4 2022

Feb 14, 2023

BUY
$9.37 - $13.8 $1.48 Million - $2.18 Million
157,752 New
157,752 $1.83 Million
Q1 2022

May 12, 2023

BUY
$6.52 - $12.27 $2.88 Million - $5.43 Million
442,248 Added 280.34%
600,000 $5.78 Million
Q1 2022

May 09, 2022

SELL
$6.52 - $12.27 $4.59 Million - $8.63 Million
-703,400 Closed
0 $0
Q4 2021

Mar 09, 2022

BUY
$11.89 - $16.07 $8.36 Million - $11.3 Million
703,400 New
703,400 $8.36 Million
Q3 2021

Nov 14, 2022

BUY
$15.6 - $21.46 $11.2 Million - $15.4 Million
717,100 New
717,100 $11.6 Million
Q3 2021

Nov 05, 2021

SELL
$15.6 - $21.46 $9.36 Million - $12.9 Million
-600,000 Closed
0 $0
Q2 2021

Aug 15, 2022

BUY
$15.94 - $22.33 $9.56 Million - $13.4 Million
600,000 New
600,000 $12.6 Million
Q2 2021

Aug 10, 2021

SELL
$15.94 - $22.33 $9.56 Million - $13.4 Million
-600,000 Closed
0 $0
Q1 2021

May 09, 2022

BUY
$14.0 - $29.3 $8.4 Million - $17.6 Million
600,000 New
600,000 $9.32 Million
Q1 2021

May 07, 2021

SELL
$14.0 - $29.3 $5.6 Million - $11.7 Million
-400,000 Closed
0 $0
Q4 2020

Mar 02, 2021

BUY
$16.81 - $23.94 $6.72 Million - $9.58 Million
400,000 New
400,000 $8.4 Million
Q4 2020

Feb 10, 2021

SELL
$16.81 - $23.94 $8.08 Million - $11.5 Million
-480,769 Closed
0 $0
Q3 2020

Nov 12, 2021

BUY
$20.0 - $23.9 $9.62 Million - $11.5 Million
480,769 New
480,769 $9.71 Million

Others Institutions Holding DYN

About Dyne Therapeutics, Inc.


  • Ticker DYN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,765,400
  • Market Cap $1.55B
  • Description
  • Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...
More about DYN
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.